These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8538479)

  • 21. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial.
    Grey AB; Stapleton JP; Evans MC; Tatnell MA; Reid IR
    Ann Intern Med; 1996 Sep; 125(5):360-8. PubMed ID: 8702086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
    Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climacteric symptoms and the endometrium].
    Belaisch J; Nappi C; Affinito P; De Gezelle H; Botelho M; Oliveira HM; Martinez-Oliveira J; Gonzaga F
    J Gynecol Obstet Biol Reprod (Paris); 2000 Feb; 29(1):29-40. PubMed ID: 10675831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of estradiol alone or in combination with cyproterone acetate on carotid artery pulsatility index in postmenopausal women.
    De Leo V; la Marca A; Orlandi R; Crippa D; Setacci C; Petraglia F
    Maturitas; 2003 Nov; 46(3):219-24. PubMed ID: 14585525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cyclical gestagen (MPA) supplement for continuous transdermal or oral estrogen substitution in postmenopause: modification of serum lipids].
    Hänggi W; Birkhäuser MH; Malek A; Peheim E; von Hospenthal JU
    Geburtshilfe Frauenheilkd; 1993 Oct; 53(10):709-14. PubMed ID: 8270155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased activity of lecithin:cholesterol acyltransferase during short-term oral estrogen progestin replacement therapy in a group of postmenopausal women.
    Ulloa N; Verdugo C; Rios M; Sepúlveda J; Sepúlveda S; Naveas R; Calvo C
    Metabolism; 1998 Mar; 47(3):297-300. PubMed ID: 9500566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
    Gallagher JC; Kable WT; Goldgar D
    Am J Med; 1991 Feb; 90(2):171-8. PubMed ID: 1847582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect and tolerability of sequential administration of estradiol valerate and medroxyprogesterone acetate on menopausal symptoms, hormonal profile and biochemical markers in climacteric women].
    Radowicki S; Skórzewska K; Borakowska B; Wierzba W; Michalewski K
    Ginekol Pol; 2004 Jan; 75(1):39-46. PubMed ID: 15112472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause.
    Reginster JY; Christiansen C; Dequinze B; Deroisy R; Gaspard U; Taquet AN; Franchimont P
    Calcif Tissue Int; 1993 Jul; 53(1):13-6. PubMed ID: 8394191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
    Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
    Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women.
    Hilditch JR; Lewis J; Ross AH; Peter A; van Maris B; Franssen E; Charles J; Norton P; Dunn EV
    Maturitas; 1996 Jul; 24(3):177-84. PubMed ID: 8844631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch].
    Sajtos B; Herold J; Winkler UH; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of two different progestins (cyproterone acetate and norgestrel), administered in a cyclical estradiol valerate regimen, on markers of bone turnover.
    Prelević GM; Beljić T; Balint-Perić L; Petrović J; Elliesen J
    Gynecol Endocrinol; 1994 Sep; 8(3):209-14. PubMed ID: 7847107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transvaginal sonography of the endometrium in postmenopausal women: monitoring the effect of hormone replacement therapy.
    Castelo-Branco C; Puerto B; Durán M; Gratacós E; Torné A; Fortuny A; Vanrell JA
    Maturitas; 1994 May; 19(1):59-65. PubMed ID: 7935033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate.
    Lemay A; Dodin S; Cédrin I; T-Lemay L
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):341-51. PubMed ID: 7750187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
    Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.
    Imthurn B; Rosselli M; Jaeger AW; Keller PJ; Dubey RK
    J Clin Endocrinol Metab; 1997 Feb; 82(2):388-94. PubMed ID: 9024224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women.
    Egarter C; Geurts P; Boschitsch E; Speiser P; Huber J
    Acta Obstet Gynecol Scand; 1996 Apr; 75(4):386-93. PubMed ID: 8638462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.